このエントリーをはてなブックマークに追加
ID 62820
JaLCDOI
フルテキストURL
75_6_763.pdf 1.84 MB
著者
Iwata, Takehiro Department of Urology, Okayama University Hospital Kaken ID
Sadahira, Takuya Department of Urology, Okayama University Hospital
Maruyama, Yuki Department of Urology, Okayama University Hospital
Sekito, Takanori Department of Urology, Okayama University Hospital
Yoshinaga, Kasumi Department of Urology, Okayama University Hospital
Watari, Shogo Department of Urology, Okayama University Hospital
Nagao, Kentaro Department of Urology, Okayama University Hospital
Kawada, Tatsushi Department of Urology, Okayama University Hospital
Tominaga, Yusuke Department of Urology, Okayama University Hospital
Nishimura, Shingo Department of Urology, Okayama University Hospital
Takamoto, Atsushi Department of Urology, Okayama University Hospital
Sako, Tomoko Department of Urology, Okayama University Hospital
Edamura, Kohei Department of Urology, Okayama University Hospital
Kobayashi, Yasuyuki Department of Urology, Okayama University Hospital ORCID Kaken ID
Araki, Motoo Department of Urology, Okayama University Hospital ORCID Kaken ID publons researchmap
Ishii, Ayano Department of Urology, Okayama University Hospital Kaken ID publons researchmap
Watanabe, Masami Department of Urology, Okayama University Hospital Kaken ID publons researchmap
Watanabe, Toyohiko Department of Urology, Okayama University Hospital ORCID Kaken ID publons researchmap
Nasu, Yasutomo Department of Urology, Okayama University Hospital Kaken ID publons researchmap
Wada, Koichiro Department of Urology, Okayama University Hospital ORCID researchmap
抄録
The aim of this ongoing trial is to evaluate the clinical efficacy and safety of sitafloxacin (STFX) 200 mg once daily (QD) for 7 days in patients with refractory genitourinary tract infections, which include recurrent or complicated cystitis, complicated pyelonephritis, bacterial prostatitis, and epididymitis. The primary endpoint is the microbiological efficacy at 5-9 days after the last administration of STFX. Recruitment began in February 2021, and the target total sample size is 92 participants.
キーワード
genitourinary tract infections
fluoroquinolone resistance
extended-spectrum beta-lactamase
Amo Type
Clinical Study Protocol
出版物タイトル
Acta Medica Okayama
発行日
2021-12
75巻
6号
出版者
Okayama University Medical School
開始ページ
763
終了ページ
766
ISSN
0386-300X
NCID
AA00508441
資料タイプ
学術雑誌論文
言語
英語
著作権者
Copyright Ⓒ 2021 by Okayama University Medical School
論文のバージョン
publisher
査読
有り
PubMed ID
Web of Science KeyUT
NAID